Treatment and follow-up of patients with malignant haemopathies, febrile neutropaenia and tranfusions-at-risk
Bone marrow and haematopoietic stem cell transplantations in collaboration with the Hôpital Universitaire des Enfants Reine Fabiola: classical autologous and allogeneic, non myeloablative (for patients up to the age of 70); haploidentical; and cord blood
Isolation of patients with neutropaenia or aplasia
Development of new haematopoietic approaches (e.g., experimental transplantations, regenerative cellular therapies, extracorporeal photopheresis)
FielD, technologies anD MethoDs
Our dreams of yesterday have become today’s reality: as research advances, the disease retreats. PrOF DOMinique brOn, Head of the Haemato-Oncology & transplantation Department
Main areas Malignant haemopathies Management of febrile neutropaenia
Haematopoietic stem cell transplantations
Cellular therapies and regenerative medicine
aPPlieD research Translational research, in particular an important study designed to better deﬁne prognostic factors of chronic lymphocytic leukaemia and, ultimately, to provide better therapies for patients.
Cellular (and regenerative) therapy using mesenchymal stromal cells, isolated from bone marrow, cord blood and adipose tissue. These cells have the potential to accelerate haematological engraftment, to limit post-transplantation immune reactions, and to regenerate bone, adipose or muscular tissues.
Stem cell transplantation, including the development of new transplantation tech- niques (e.g., double cord blood, haplo-identical).
MEDICINE HAEMATO-ONCOLOGY MEDICINE & TRANSPLANTATION